Anavex 2-73 Safely Aids Cognition in Parkinson’s Dementia, Phase 2 Trial Reports
Anavex 2-73 (blarcamesine), a potential oral therapy to slow cognitive decline due to Alzheimer’s and other neurological disorders, was found to be safe and to lead to clinically meaningful, dose-dependent improvements in cognition in people with Parkinson’s disease dementia (PDD) treated in a Phase 2 trial. Anavex…